Academic, industry, and FDA collaboration is key to personalized treatment manufacturing, says Aldevron’s Max Sellman at BPI this week.

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the placement of the 1 ...

One of the biggest advantages of the new polymer-based nanoparticles over current lipid-based models is the potential for low ...

News headlines have blasted in recent weeks that the carrier of the potentially deadly parasite Trypanosoma cruzi —the cause ...

In the fast-evolving field of medical science, a new artificial intelligence model may be about to change the way mRNA-based ...

When doctors prescribe oxybutynin, it's usually for an unglamorous problem: bladder incontinence. But researchers have ...

When doctors prescribe oxybutynin, it's usually for an unglamorous problem: bladder incontinence. But researchers have discovered a surprising new ...

Excessive alcohol consumption traps liver cells in limbo between functional and regenerative states, disrupting the liver's ...

New tool classifies cell types from single-cell RNA sequencing data with speed and accuracy, processing 650k cells in 6 ...

Excessive alcohol consumption can disrupt the liver's unique regenerative abilities by trapping cells in limbo between their ...